OBR Daily Commentary

forumImage

FDA Taking New Steps to Better Inform Physicians about Biosimilars Through Education about these Potentially Cost-Saving Options

(FDA.gov/FDA Voice) Oct 23, 2017 - The cost of prescription drugs is an ongoing concern, however, a growing market for potentially lower-cost biological products called biosimilars can offer more competition and options for patients.

Read Article arrow

Winston Wong, PharmD (Posted: November 02, 2017)

quotesEducating physician about biosimilars is a big step to help gain confidence that the biosimilar will indeed produce a similar clinical benefit. But will not drive biosimilar utilization to expectations. First, we need to get the approved biosimilars out of court. The legal system is hold the biosimilars hostage. Second, with the current biosimilars only representing a 15-25% discount off the reference product, this is clearly within reach of the reference products to reduce their cost down to near parity. At a near parity cost, why switch. In short, much more than education is needed to drive biosimilar utilization, as as usual, the main factor will be the "$".quotes

Add Comment 1 Comment
forumImage

Why Drug Makers Should Worry About Anthem's New PBM

(Forbes) Oct 19, 2017 - News that Anthem will launch its own new pharmacy benefit manager in 2020 in partnership with CVS Health should worry the pharmaceutical industry.

Read Article arrow

Winston Wong, PharmD (Posted: October 22, 2017)

quotesIt is interesting to see how situations come back around. Recall that Anthem Pharmacy Management once existed, prior to signing on with ESI. Now they are starting up the old strategy again. Whether there is more transparency or not, the one thing that will happen is that Anthem will have greater control of the over all pharmacy strategy.quotes

Add Comment 1 Comment
forumImage

Trajectories of Injectable Cancer Drug Costs After Launch in the United States

(Journal of Clinical Oncology) October 10, 2017 - Cancer drug prices at launch have increased in recent years. It is unclear how individual drug prices change over time after launch and what market determinants influence these changes.

Read Article arrow

Winston Wong, PharmD (Posted: October 19, 2017)

quotesThis study is very similar to the study completed by Peter Bach in 2015. Dr Bach looked at the initial cost of the drug when released, and then tracked cost increases. This study confirms his finding. No matter how you slice and dice the data, the bottom line is that we are still an a time of unsustainable cost increases. The next step is to compare the increases in the US vs. Europe.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...